Exhibit 99.1 Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026 Enrollment in registrational STARBORN-1 trial now expected to complete in early 1Q'2027; expect to initiate a rolling BLA submission for TARA-002 in LMs in 2H 2027 Completed enrollment of THRIVE-3 Phase 2b dosing cohort evaluating IV Choline Chloride in patients ...